CONTROL OF COMMUNICABLE DISEASES AND CONDITIONS WHICH MAY SIGNIFICANTLY AFFECT PUBLIC HEALTH, Definitions, Notifiable Diseases or Conditions to Be Reported, Human, Notification by Laboratories, Notification by Others, Notifiable Disease Case Report ...

 

DEPARTMENT OF HEALTH
Division of Disease Control

RULE NO: RULE TITLE
64D-3: CONTROL OF COMMUNICABLE DISEASES AND CONDITIONS WHICH MAY SIGNIFICANTLY AFFECT PUBLIC HEALTH
64D-3.001: Definitions
64D-3.002: Notifiable Diseases or Conditions to Be Reported, Human
64D-3.003: Notification by Laboratories
64D-3.0031: Notification by Others
64D-3.004: Notifiable Disease Case Report Content
64D-3.005: Authority, DOH County Health Department Director or Administrator and State Health Officer
64D-3.006: Reports, Medical Facilities and Freestanding Radiation Therapy Centers
64D-3.007: Quarantine, Requirements
64D-3.0071: Public Health Emergency
64D-3.008: Transportation and Removal of Quarantined Persons and Animals
64D-3.009: Laboratory Examinations, Release From Quarantine
64D-3.010: Quarantine Disinfection Procedures, Concurrent and Terminal
64D-3.011: Control of Communicable Diseases, Public and Nonpublic Schools, Grades Preschool, and Kindergarten Through 12; Forms and Guidelines
64D-3.012: Diseased Animals
64D-3.013: Procedures for Control of Specific Communicable Diseases
64D-3.014: Sensitive Situations
64D-3.015: Diseases Designated as Sexually Transmissible Diseases
64D-3.016: Reporting Requirements for Practitioners for Sexually Transmissible Diseases (STDs), Including HIV and AIDS
64D-3.017: Reporting Requirements for Laboratories
64D-3.018: Partner Notification
64D-3.019: Blood Testing of Pregnant Women
64D-3.020: Enforcement and Penalties
64D-3.021: Definitions
64D-3.022: Reporting Requirements for Individuals
64D-3.023: Reporting Requirements for Laboratories
64D-3.024: Patient Treatment and Follow-up
64D-3.025: Allocation Methodology for the Distribution of Funds Appropriated for Tuberculosis Control
64D-3.026: Execution of Certificate for Involuntary Hold
64D-3.027: Reporting of Congenital Anomalies
64D-3.028: Definitions
64D-3.029: Table of Notifiable Diseases or Conditions to Be Reported
64D-3.030: Notification by Practitioners
64D-3.031: Notification by Laboratories
64D-3.032: Notification by Medical Facilities
64D-3.033: Notification by Others
64D-3.034: Cancer Reporting
64D-3.035: Congenital Anomaly Reporting
64D-3.036: Notifiable Disease Case Report Content is Confidential
64D-3.037: Authority of the DOH County Health Department Director or Administrator and State Health Officer
64D-3.038: Quarantine Orders and Requirements
64D-3.039: Diseased Animals
64D-3.040: Procedures for Control of Specific Communicable Diseases
64D-3.041: Epidemiological Investigations
64D-3.042: STD Testing Related to Pregnancy
64D-3.043: Tuberculosis Treatment and Follow-up
64D-3.044: Allocation Methodology for the Distrubution of Funds Appropriated for Tuberculosis Control
64D-3.045: Execution of Certificate for Involuntary Hold for Tuberculosis
64D-3.046: Immunization Requirements: Public and Nonpublic Schools, Grades Preschool, and Kindergarten Through 12, and Adult Education Classes
64D-3.047: Enforcement and Penalties

NOTICE OF CHANGE

Notice is hereby given that the following changes have been made to the proposed rule in accordance with subparagraph 120.54(3)(d)1., F.S., published in Vol. 32 No. 24, June 16, 2006 issue of the Florida Administrative Weekly.

(TEXT OF PROPOSED RULE CHANGES)

64D-3.001 Definitions. Repealed.

Editorial Note: See 64D-3.028

 

64D-3.002 Notifiable Diseases or Conditions to Be Reported, Human. Repealed.

Editorial Note: See 64D-3.029

 

64D-3.003 Notification by Laboratories. Repealed.

Editorial Note: See 64D-3.031

 

64D-3.0031 Notification by Others, Repealed.

Editorial Note: See 64D-3.033

 

64D-3.004 Notifiable Disease Case Report Content. Repealed.

Editorial Note: See 64D-3.036

 

64D-3.005 Authority, DOH County Health Department Director or Administrator and State Health Officer. Repealed.

Editorial Note: See 64D-3.037

 

64D-3.006 Reports, Medical Facilities and Freestanding Radiation Therapy Centers. Repealed.

Editorial Note: See 64D-3.032 & 64D-3.034

 

64D-3.007 Quarantine, Requirements. Repealed.

Editorial Note: See 64D-3.038

 

64D-3.0071 Public Health Emergency. Repealed.

Editorial Note: See 64D-3.038

 

64D-3.008 Transportation and Removal of Quarantined Persons and Animals. Repealed.

Editorial Note: See 64D-3.038

 

64D-3.009 Laboratory Examinations, Release From Quarantine. Repealed.

Editorial Note: See 64D-3.038

 

64D-3.010 Quarantine Disinfection Procedures, Concurrent and Terminal. Repealed.

Editorial Note: See 64D-3.038

 

64D-3.011 Control of Communicable Diseases, Public and Nonpublic Schools, Grades Preschool, and Kindergarten Through 12; Forms and Guidelines. Repealed.

Editorial Note: See 64D-3.046

 

64D-3.012 Diseased Animals. Repealed.

Editorial Note: See 64D-3.039

 

64D-3.013 Procedures for Control of Specific Communicable Diseases. Repealed.

Editorial Note: See 64D-3.040

 

64D-3.014 Sensitive Situations. Repealed.

Editorial Note: See 64D-3.038(4)(a)

 

64D-3.015 Diseases Designated as Sexually Transmissible Diseases. Repealed.

Editorial Note: See 64D-3.028(22)

 

64D-3.016 Reporting Requirements for Practitioners for Sexually Transmissible Diseases (STDs), Including HIV and AIDS. Repealed.

Editorial Note: See 64D-3.030

 

64D-3.017 Reporting Requirements for Laboratories. Repealed.

Editorial Note: See 64D-3.031

 

64D-3.018 Partner Notification. Repealed.

Editorial Note: See 64D-3.041

 

64D-3.019 Blood Testing of Pregnant Women. Repealed.

Editorial Note: See 64D-3.042

 

64D-3.020 Enforcement and Penalties. Repealed.

Editorial Note: See 64D-3.047

 

64D-3.021 Definitions. Repealed

Editorial Note: See 64D-3.028

 

64D-3.022 Reporting Requirements for Individuals. Repealed

Editorial Note: See 64D-3.030

 

64D-3.023 Reporting Requirements for Laboratories. Repealed

Editorial Note: See 64D-3.031

 

64D-3.024 Patient Treatment and Follow-up. Repealed

Editorial Note: See 64D-3.043

 

64D-3.025 Allocation Methodology for the Distribution of Funds Appropriated for Tuberculosis Control. Repealed

Editorial Note: See 64D-3.044

 

64D-3.026 Execution of Certificate for Involuntary Hold. Repealed

Editorial Note: See 64D-3.045

 

64D-3.027 Reporting of Congenital Anomalies. Repealed

Editorial Note: See 64D-3.035

 

64D-3.028 Definitions.

(18) “Human Immunodeficiency Virus (HIV) Exposed Newborn” – An infant 18 months of age or younger born to a HIV infected woman.

Editorial Note: Formerly 64D-3.001, 64D-3.014, 64D-3.015 & 64D-3.021.

 

64D-3.029 Diseases or Conditions to Be Reported.

(1) Diseases or conditions listed in subsection (3) below are of public health significance identified by the Department as of the date of these rules which must be reported by the practitioner, hospital, laboratory, or other individuals via telephone (with subsequent written report within 72 hours, see Rules 64D-3.030-.033, F.A.C.), facsimile, electronic data transfer, or other confidential means of communication to the County Health Department having jurisdiction for the area in which the office of the reporting practitioner, hospital, laboratory or patient’s residence is located consistent with the specific section and time frames in subsection (3) below relevant to the practitioners, hospitals and laboratories, respectively. Reporters are not prohibited from reporting diseases and/or conditions not listed by rule.

(2) Definitions to be used with subsection (3) below:

(a) “Notifiable Diseases or Conditions” – The definitions of “case” and “suspected case” for reportable diseases or conditions are set forth in “Surveillance Case Definitions for Select Reportable Diseases in Florida,” incorporated by reference, available online at: www.doh.state.fl.us/ disease_ctrl/epi/topics/surv.htm. For any disease or condition for which Florida surveillance case definitions do not exist, the CDC case definitions set forth in Nationally Notifiable Infectious Diseases, Definition of Terms Used in Case Classification, incorporated by reference, available online at: www.cdc.gov/epo/dphsi/casedef/ definition_of_terms.htm should be used. Also see the footnotes to subsection (3).

(b) “Suspect Immediately” – A notifiable condition or urgent public health importance. Report without delay upon the occurrence of any of the following: Initial suspicion, receipt of a specimen with an accompanying request for an indicative or confirmatory test, findings indicative thereof, or suspected diagnosis. Reports that cannot timely be made during the County Health Department business day shall be made to the County Health Department after-hours duty official. If unable to do so, the reporter shall contact the Florida Department of Health after hours duty official at [phone].

(c) “Immediately” – A notifiable condition of urgent public health importance. Report without delay upon the occurrence of any of the following: An indicative or confirmatory test, findings indicative thereof, or diagnosis. Reports that cannot timely be made during the County Health Department business day shall be made to the County Health Department after-hours duty official. If unable to do so, the reporter shall contact the Florida Department of Health after hour’s duty official at [phone].

(d) “Next Business Day” – Report before the closure of the County Health Department’s next business day following suspicion or diagnosis.

(e) “Other” – Report consistent with the instruction in and footnotes to (3) below.

(3) “Table of Notifiable Diseases or Conditions to be Reported”

 

Practitioner Reporting					Laboratory Reporting
Notifiable Diseases or Conditions	Timeframes				Evidence of current or recent infection with etiological agents	Submit isolates or specimens for confirmation*1	Timeframes
	Suspect Immediately	Immediately	Next Business Day	Other			Suspect Immediately	Immediately	Next Business Day	Other
Any disease outbreak in a community, hospital or other institution or a foodborne or waterborne outbreak	X	X			Any grouping or clustering of patients having similar etiological agents that may indicate the presence of a disease outbreak		X	X
Any grouping or clustering of patients having similar disease, symptoms or syndromes that may indicate the presence of a disease outbreak including those of biological agents associated with terrorism	X	X			Any grouping or clustering of patients having similar etiological agents that may indicate the presence of a disease outbreak including those of biological agents associated with terrorism.		X	X
Acquired Immune Deficiency Syndrome (AIDS)				2 Weeks	Not Applicable
Anthrax	X	X			Bacillus anthracis	X	X	X
Botulism, foodborne	X	X			Clostridium botulinum or botulinum toxin	X	X	X
Botulism, infant			X		Clostridium botulinum or botulinum toxin	X			X
Botulism, other (includes wound and unspecified)	X	X			Clostridium botulinum or botulinum toxin	X	X	X
Brucellosis	X	X			Brucella abortus, B. melitensis, B. suis, B. canis	X	X	X
California serogroup virus neuroinvasive and non-neuroinvasive disease			X		California encephalitis virus, Jamestown Canyon, Keystone, Lacrosse, snowshoe hare, trivittatus				X
Campylobacteriosis			X		Campylobacter species				X
Cancer (except non-melanoma skin cancer, and including benign and borderline intracranial and CNS tumors)*2				6 Months	Pathological or tissue diagnosis of cancer (except non-melanoma skin cancer and including benign and borderline intracranial and CNS tumors)					6 Months
CD-4	Not Applicable				CD-4 absolute count and percentage of total lymphocytes*3					3 days
Chancroid			X		Haemophilus ducreyi				X
Chlamydia			X		Chlamydia trachomatis				X
Chlamydia in pregnant women and neonates			X		Chlamydia trachomatis				X
Chlamydia in children < 12 years of age*4			X		Chlamydia trachomatis				X
Cholera	X	X			Vibrio cholerae	X	X	X
Ciguatera fish poisoning (Ciguatera)			X		Not Applicable
Clostridium perfringens, epsilon toxin (disease due to)			X		Clostridium perfringens, epsilon toxin				X
Congenital Anomalies*5				6 Months	Not Applicable
Conjunctivitis in neonates < 14 days old			X		Not Applicable
Creutzfeld-Jakob disease (CJD)*6			X		14-3-3 protein from CSF or any brain pathology suggestive of CJD*6				X
Cryptosporidiosis			X		Cryptosporidium parvum				X
Cyclosporiasis			X		Cyclospora cayetanensis	X			X
Dengue			X		Dengue virus				X
Diphtheria	X	X			Corynebacterium diphtheriae	X	X	X
Eastern equine encephalitis virus neuroinvasive and non-neuroinvasive disease			X		Eastern equine encephalitis virus	X			X
Ehrlichiosis, human granulocytic (HGE)			X		Ehrlichia phagocytophilia.				X
Ehrlichiosis, human monocytic (HME)			X		Ehrlichia chaffeensis				X
Ehrlichiosis, human other or unspecified agent			X		Ehrlichia species other				X
Encephalitis, other (non-arboviral)			X		Isolation from or demonstration in brain or central nervous system tissue or cerebrospinal fluid, of any pathogenic virus				X
Enteric disease due to Escherichia coli O157:H7		X			Escherichia coli O157:H7	X		X
Enteric disease due to other pathogenic Escherichia coli*7		X			Escherichia coli*7			X
Giardiasis (acute)			X		Giardia species				X
Glanders	X	X			Burkholderia mallei,	X	X	X
Gonorrhea			X		Neisseria gonorrhoeae				X
Gonorrhea in children < 12 years of age*4			X		Neisseria gonorrhoeae				X
Gonorrhea in pregnant women and neonates			X		Neisseria gonorrhoeae				X
Gonorrhea (Antibotic Resistant)			X		Neisseria gonorrhoeae*8				X
Graunuloma Inguinale			X		Calymmatobacterium granulomatis				X
Haemophilus influenzae, meningitis and invasive disease	X	X			Haemophilus influenzae	X	X	X
Hansen disease (Leprosy)			X		Mycobacterium leprae				X
Hantavirus infection		X			Hantavirus	X		X
Hemolytic uremic syndrome		X			Not Applicable
Hepatitis A*9		X			Hepatitis A*9			X
Hepatitis B, C, D, E and G Virus*9			X		Hepatitis B, C, D, E and G Virus*9				X
Hepatitis B surface antigen (HBsAg)-positive in a pregnant woman or a child up to 24 months old			X		Hepatitis B surface antigen (HBsAg)				X
Herpes simplex virus (HSV) in infants up to six (6) months of age with disseminated infection with involvement of liver, encephalitis and infections limited to skin, eyes and mouth*10			X		HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture*10				X
HSV  anogenital in children < 12 years of age*4*10			X		HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture*10				X
Human immunodeficiency virus (HIV)				2 Weeks	Repeatedly reactive enzyme immunoassay, followed by a positive confirmatory tests, (e.g. Western Blot, IFA): Positive result on any HIV virologic test (e.g. p24 AG, Nucleic Acid Test (NAT/NAAT) or viral culture). All viral load (detectable and undetectable) test results.*11					3 days
Human immunodeficiency virus (HIV) Exposed Newborn  infant < 18 months of age born to a HIV infected woman			X		Not Applicable
Human papilloma virus (HPV) associated laryngeal papillomas or recurrent respiratory papillomatosis in children <6 years of age*4			X		HPV DNA				X
HPV  anogenital in children <12 years of age*4			X		HPV DNA				X
HPV cancer associated strains*12			X		DNA typing of HPV strains 16, 18, 31, 33, 35, 36, 45 Abnormal histologies consistent with Bethesda 2001 Terminology*13				X
Influenza due to novel or pandemic strains	X	X			Isolation of influenza virus from humans of a novel or pandemic strain	X	X	X
Influenza-associated pediatric mortality in persons aged < 18 years		X			Influenza virus  associated pediatric mortality in persons aged <18 years (if known)	X		X
Lead poisoning*14			X		All blood lead tests with detectable blood lead values*14				X
Legionellosis			X		Legionella species				X
Leptospirosis			X		Leptospira interrogans				X
Listeriosis		X			Listeria monocytogenes			X
Lyme disease			X		Borrelia burgdorferi				X
Lymphogranuloma Venereum (LGV)			X		Chlamydia trachomatis				X
Malaria			X		Plasmodium falciparum, P. vivax, P. ovale, P. malariae	X			X
Measles (Rubeola)	X	X			Measles virus*15	X	X	X
Melioidosis	X	X			Burkholderia pseudomallei	X	X	X
Meningitis, bacterial, cryptococcal and mycotic (other than meningococcal or H. influenzae or pneumococcal)			X		Isolation or demonstration of any bacterial or fungal species in cerebrospinal fluid				X
Meningococcal Disease, includes meningitis and meningococcemia	X	X			Neisseria meningitidis (serogroup needed)	X	X	X
Mercury poisoning			X		Laboratory results as specified in the surveillance case definition for mercury poisoning				X
Mumps			X		Mumps virus				X
Neurotoxic shellfish poisoning		X			Laboratory results as specified in the surveillance case definition for Neurotoxic shellfish poisoning			X
Pertussis		X			Bordetella pertussis			X
Pesticide-related illness and injury			X		Laboratory results as specified in the surveillance case definition for pesticide related illness and injury				X
Plague	X	X			Yersinia pestis	X	X	X
Poliomyelitis	X	X			Poliovirus	X	X	X
Psittacosis (Ornithosis)			X		Chlamydophila psittaci (formerly known as Chlamydia psittaci)	X			X
Q Fever			X		Coxiella burnetii	X			X
Rabies, animal		X			Rabiesvirus		X	X
Rabies, human		X			Rabiesvirus		X	X
Rabies, possible exposure*16	X	X			Not Applicable
Ricin toxicity	X	X			Ricin toxin (from Ricinus communis castor beans)	X	X	X
Rocky Mountain spotted fever			X		Rickettsia rickettsii				X
Rubella, including congenital	X	X			Rubella virus*15	X	X	X
St. Louis encephalitis (SLE) virus neuroinvasive and non-neuroinvasive disease			X		St. Louis encephalitis virus	X			X
Salmonellosis			X		Salmonella species by species serogroup and serotype				X
Saxitoxin poisoning including Paralytic shellfish poisoning (PSP)			X		Saxitoxin				X
Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV) disease	X	X			SARSassociated coronavirus (SARS-CoV)	X	X	X
Shigellosis			X		Shigella species by species serogroup				X
Smallpox	X	X			Variola virus (orthopox virus)	X	X	X
Staphylococcus aureus with intermediate or full resistance to vancomycin (VISA,VRSA)		X			Staphylococcus aureus with intermediate or full resistance to vancomycin (VISA, VRSA); Laboratory results as specified in the surveillance case definition.	X		X
Staphylococcus enterotoxin B		X			Staphylococcus enterotoxin B	X		X
Streptococcal disease, invasive, Group A			X		Streptococcus pyogenes, Group A, isolated from a normally sterile site (does not include throat specimens)				X
Streptococcus pneumoniae, invasive disease	Not Applicable				Streptococcus pneumoniae isolated from a normally sterile site				X
Streptococcus pneumoniae, invasive disease in children < 5 years, drug sensitive and resistant			X		Streptococcus pneumoniae isolated from a normally sterile site				X
Syphilis			X		Treponema pallidum				X
Syphilis in pregnant women and neonates		X			Treponema pallidum			X
Tetanus			X		Clostridium tetani				X
Toxoplasmosis, acute			X		Toxoplasma gondii				X
Trichinellosis (Trichinosis)			X		Trichinella spiralis				X
Tuberculosis (TB)*17			X		Mycobacterium tuberculosis complex*17				X
Tularemia	X	X			Francisella tularensis	X	X	X
Typhoid fever		X			Salmonella typhi	X		X
Typhus fever (epidemic)	X	X			Rickettsia prowazekii	X	X	X
Typhus fever (endemic)			X		Rickettsia typhi, R. felis				X
Vaccinia disease	X	X			Vaccinia virus	X	X	X
Varicella (ChickenPox)*18			X		Varicella virus				X
Varicella mortality			X		Varicella virus				X
Venezuelan equine encephalitis virus neuroinvasive and non-neuroinvasive	X	X			Venezuelan equine encephalitis virus	X	X	X
Vibriosis (Vibrio infections, other than Cholera)			X		All non-cholera Vibrio species including, V. alginolyticus, V. damsela, V. fluvialis, V. furnissii, V. hollisae, V. mimicus, V. parahaemolyticus, V. vulnificus	X			X
Viral hemorrhagic fevers	X	X			Ebola, Marburg, Lassa, Machupo viruses	X	X	X
West Nile virus neuroinvasive and non-neuroinvasive disease			X		West Nile virus	X			X
Western equine encephalitis virus neuroinvasive and non-neuroinvasive disease			X		Western equine encephalitis virus	X			X
Yellow fever	X	X			Yellow fever virus	X		X

 

*9 – Special reporting requirements for Hepatitis:

a. Positive results should be accompanied by any hepatitis testing conducted; and

b. All serum aminotransferase levels.

*10 – A 4-fold titer rise in paired sera by various serological tests confirmatory of primary infection; presence of herpes-specific IgM suggestive but not conclusive evidence of primary infection.

*11 – Special requirements for STARHS (Serologic Testing Algorithm for Recent HIV Seroconversion):

a. Each laboratory that reports a confirmed positive HIV test in persons 13 years of age and older must also report a serologic testing algorithm for recent HIV seroconversion (STARHS) test result.

b. In lieu of producing this test result, each laboratory that reports a confirmed positive HIV test must submit a sample for additional testing using STARHS (Serologic Testing Algorithm for Recent HIV Seroconversion). The laboratory is permitted to send the remaining blood specimen or an aliquot of at least 0.5 ml to the Florida Department of Health, Bureau of Laboratories, 1217 Pearl Street, Jacksonville, Florida 32202-3926.

c. Laboratories electing to send a blood specimen will contact the Florida Department of Health, Bureau of Laboratories at [phone] to receive specimen maintenance and shipping instructions.

d. Nationally based laboratories with an existing contract to ship specimens directly to a STARHS laboratory designated by the National Centers for Disease Control and Prevention will not be required to send a specimen to the Florida Department of Health Laboratory.

*12 – Practitioners need only to report the presence of cancer associated strains, not abnormal cytologies to the Florida Department of Health, Bureau of STD Prevention and Control, 4052 Bald Cypress Way, Bin A-19, Tallahassee, Florida 32399-1712, [phone].

*13 – Special reporting requirements for abnormal histologies:

a. Report only classifications consistent with Bethesda 2001 Terminology of ASC-US, ASC-H, HSIL, LSIL, CIN 1, CIN 2, CIN 3 and AGC to the Florida Department of Health, Bureau of STD Prevention and Control, 4052 Bald Cypress Way, Bin A-19, Tallahassee, Florida 32399-1712, [phone].

b. All such reports must be received by the Department electronically in HL-7 format.

*14 – Special reporting requirements for reporting blood lead tests:

a. All blood lead tests are considered evidence of a suspected case and are to be reported to the Florida Department of Health, Bureau of Community Environmental Health, Childhood Lead Poisoning Prevention Program, 4052 Bald Cypress Way, Bin A08, Tallahassee, Florida 32399-1712, [phone].

b. All such reports must be received by the Department electronically.

*15 – IgM serum antibody or viral culture test orders for measles (rubeola) or rubella should be reported as suspect immediately, but not IgG results.

*16 – Includes a bite or other significant exposure to a human or domestic animal (including all pets and livestock) by an animal:

a. That results in rabies prophylaxis for the person exposed, rabies testing and/or quarantine of the animal causing the exposure; or

b. That is capable of transmitting herpes B viruses (includes exposures from nonhuman primates.

*17 – Special reporting requirements for Tuberculosis:

a. Test results must also be submitted by laboratories to the Department of Health, Bureau of Tuberculosis and Refugee Health, 4052 Bald Cypress Way, Bin A20, Tallahassee, Florida 32399-1717, [phone];

b. The 15-digit spoligotype (octal code) must be reported. If the spoligotyping is not available, the isolate must be submitted to the Department of Health, Bureau of Laboratories, 1217 Pearl Street, Jacksonville, Florida 32202-3926, [phone]. The Department will provide the mailing materials and pay mailing costs.

*18 – Special reporting requirements for Varicella (chickenpox) – Besides the information required to be reported in subsection 64D-3.030(3), F.A.C., practitioners shall also provide date of vaccination.

Specific Authority 381.0011(13), 381.003(2), 381.0031(6), 384.33, 392.53(2), 392.66 FS. Law Implemented 381.0011(4), 381.003(1), 381.0031(1), (2), (6), 383.06, 384.23, 384.25, 385.202, 392.53 FS. History–New_______.

Editorial Note: Formerly 64D-3.002.

 

64D-3.030 Notification by Practitioners.

(3) Any report of a notifiable disease or condition required by this rule, except for cancer, congenital anomalies and HIV/AIDS, shall be reported on the Florida Department of Health Disease Report Form (DH Form 2136, 3/06), incorporated by reference, available at the Department of Health, Division of Disease Control, 4052 Bald Cypress Way, Bin A-09, Tallahassee, FL 32399-1714, or on a form supplied by the provider that includes the following:

(a) The patient’s:

1. First and last name, including middle initial;

2. Address, including city, state and zip code;

3. Telephone number, including area code;

4. Date of birth;

5. Sex;

6. Race;

7. Ethnicity (specify if of Hispanic descent or not of Hispanic descent);

8. Pregnancy status if applicable;

9. Social Security number;

10. Date of onset of symptoms;

11. Diagnosis.

(5) Special reporting requirements for HIV and AIDS:

(a) All cases of HIV or AIDS, which meet the Centers for Disease Control and Prevention (CDC) case definitions set forth in CDC Guidelines for National Human Immunodeficiency Virus Case Surveillance, Including Monitoring for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome, published in Morbidity and Mortality Weekly Report (MMWR) Vol. 48 [RR-13, December 10, 1999], incorporated by reference, available online at: www.cdc.gov/mmwr/PDF/RR/ RR4813.pdf, shall be reported on the Adult HIV/AIDS Confidential Case Report, CDC 50.42A Rev. 01/2003, incorporated by reference, or the Pediatric HIV/AIDS Confidential Case Report, CDC 50.42B Rev. 01/2003, incorporated by reference, along with the Department of Health Addendum for Adult HIV/AIDS Confidential Case Report, DH Form 2134, incorporated by reference. All forms are available at county health departments or at the Department of Health, Bureau of HIV/AIDS, 4052 Bald Cypress Way, Bin A-09,Tallahassee, Florida 32399-1715.

(b) HIV exposed newborns shall be reported on the Pediatric HIV/AIDS Confidential Case Report, CDC 50.42B Rev. 01/2003, incorporated by reference in paragraph 64D-3.030(5)(b), F.A.C.

Editorial Note: Formerly 64D-3.016 and 64D-3.022.

 

64D-3.031 Notification by Laboratories.

(3) To allow follow-up of laboratory findings suggestive of or diagnostic of diseases or conditions in the Table of Notifiable Diseases or Conditions, the form upon which the information will be reported shall be furnished by the laboratory that includes the following information:

(a) The Patient’s:

1. First and last name, including middle initial;

2. Address including street city, state and zip code;

3. Phone number, including area code;

4. Date of birth;

5. Sex;

6. Race;

7. Ethnicity (specify if of Hispanic descent or not of Hispanic descent);

8. Pregnancy status if applicable;

9. Social Security number;

(4) Laboratories located out of state, licensed under Part 1, Chapter 483, F.S., who collect specimens in Florida or who receive the initial order for testing from a practitioner, blood bank, plasmapheresis center or other health care provider located in Florida, shall report in the same way as if the findings had been made by a laboratory located in Florida.

(5) Upon the Department’s implementation of its Electronic Laboratory Reporting System (ELR) for laboratory findings suggestive of or diagnostic of diseases or conditions, reports will be submitted electronically to the Department using Health Level Seven (HL7) version 2.3.1 format. A CDC Implementation Guide for Transmission of Laboratory-Based Reporting of Public Health Information using version 2.3.1 of the Health Level Seven (HL7) Standard Protocol, incorporated by reference, is available at the Department of Health, ELR Project, 4052 Bald Cypress Way, Bin A-12, Tallahassee, Florida 32399-1715.

(7) In order to study disease incidence, each laboratory licensed to perform tests for any notifiable disease or condition shall report the test volume for each related diagnostic test performed for the notifiable diseases listed in Rule 64D-3.029, F.A.C.

(a) Reports are to be filed annually on or before April 1 of each year to the Department electronically in a format agreed upon by the department and the laboratory with the following information:

Editorial Note: Formerly 64D3.003, 64D-3.017 & 64D-3.023.

 

64D-3.032 Notification by Medical Facilities.

(1) The chief administrative officer of each facility licensed under Chapter 395, F.S., or freestanding radiation therapy centers, as defined in Section 408.07(20), F.S., shall either personally or by appointing an individual from the staff, hereinafter referred to as “reporting individual,” report all cases or suspect cases of diseases or positive laboratory finding indicating the presence of a disease or condition listed in Rule 64D-3.029, F.A.C., in all persons admitted to, attended to, or residing in the facility per this rule.

(2) The chief administrative officer of each Department of Defense or Veterans Administrative (VA) facility located in Florida are requested to appoint an individual from the staff, hereinafter referred to as “reporting individual,” report all cases or suspect cases of diseases or positive laboratory finding indicating the presence of a disease or condition listed in Rule 64D-3.029, F.A.C., in all persons admitted to, attended to, or residing in the facility per this rule.

(3) Reporting of a case or suspected case of disease or condition or positive laboratory findings by a facility or center fulfills the requirements of the licensed practitioner and laboratory director to report. It remains the responsibility of the practitioner or laboratory director to ensure that the report is made as stipulated in Rule 64D-3.029, F.A.C.

(4) Each facility that reports a notifiable disease or condition or a positive laboratory finding indicating the presence of a notifiable disease shall make its records for such diseases or conditions available for on-site inspection by the Department or its authorized representatives.

Specific Authority 381.0011(13), 381.003(2), 381.0031(5), 381.0031(6), 383.06, 384.33, 385.202(5), 392.66 FS. Law Implemented 381.0011, 381.003, 381.0031, 384.25, 385.202, 392.53 FS. History–New_________.

Editorial Note: Formerly 64D-3.006(1)(2).

 

64D-3.033 Notification by Others.

Editorial Note: Formerly 64D-3.0031.

 

64D-3.034 Cancer Reporting.

(1) Reporting Requirements:

(c) The data items, coding schemes, definitions, record layouts and reporting procedures are to follow the guidance provided in the Florida Cancer Data System Data Acquisition Manual (2005, or current year edition), incorporated by reference, available at: http://fcds.med.miami.edu/inc/ downloads.shtml.

Editorial Note: Formerly 64D-3.006(3), (5).

 

64D-3.035 Congenital Anomaly Reporting.

Specific Authority 381.0011(13), 381.0031(6) FS. Law Implemented 381.0011(7), 381.0031 FS. History–New________.

Editorial Note: Formerly 64D-3.027.

 

64D-3.036 Notifiable Disease Case Report Content is Confidential.

Editorial Note: Formerly 64D-3.004.

 

64D-3.037 Authority of the DOH County Health Department Director or Administrator and State Health Officer.

Editorial Note: Formerly 10D-3.074, 64D-3.005

 

64D-3.038 Quarantine Orders and Requirements.

(6) For zoonosis control and prevention, any animal determined by the Department to be a significant threat to human health shall be humanely euthanized in accordance with the American Veterinary Medical Association’s 2000 Report of the AVMA Panel on Euthanasia, incorporated by reference, available from the Florida Department of Health, Bureau of Epidemiology, 4052 Bald Cypress Way, Bin A-12, Tallahassee, Florida 32399-1720. Such an order shall be issued in writing.

Editorial Note: Formerly 64D-3.007, 64D-3.0071, 64D-3.008, 64D-3.009 and 64D-3.010.

 

64D-3.039 Diseased Animals.

Editorial Note: Formerly 64D-3.012.

 

64D-3.040 Procedures for Control of Specific Communicable Diseases.

(1) Psittacosis (Ornithosis).

(b) Birds suspected of being infected or having been associated with infected birds shall not be removed from any premises until the State Health Officer or the county health department director or administrator or their designee, has investigated the situation and issued orders which may include quarantine, laboratory examination or prescribed treatment according to recommendations of the National Association of State Public Health Veterinarians, Inc., published in the Compendium of Measures to Control Chlamydophila psittaci (formerly Chlamydia psittaci) Infection Among Humans (Psittacosis) and Pet Birds (Avian Chlamydiosis), 2006, incorporated by reference, available from the Department of Health, Division of Environmental Health, 4052 Bald Cypress Way, Bin A-08, Tallahassee, Florida 32399-1720.

(2) Rabies Control in Humans.

(b) Prevention in Humans – Persons bitten or otherwise exposed to suspect rabid animals shall be evaluated for post-exposure treatment by the county health department director or medical director or their designee according to recommendations of Human Rabies Prevention- United States, 1999, Recommendations of the Advisory Committee on Immunization Practices (ACIP), published in the Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, Vol. 48, No. RR-1, January 8, 1999, incorporated by reference, available online at: www.cdc.gov/ mmwr/PDF/rr/rr4801.pdf.

(3) Rabies Control in Animals.

(b) The county health department director or administrator or their designee shall cause to be captured, confined or seized suspected rabid animals and isolate and quarantine or humanely euthanize and provide for laboratory examination, as outlined in the guidebook, Rabies Prevention and Control in Florida 2006, incorporated by reference, available at: www.myflorideh.com/community/arboviral/Zoonoses/Rabiesg uideUpdated.pdf. This includes animals involved in human exposure (bite and non-bite) and animals exposed to rabid or suspected rabid animals. Other methods of controlling rabies in domestic or wild animals shall be administered by order of the county health department director or administrator or their designee according to recommendations of the Florida Rabies Advisory Committee.

(5) Enteric disease outbreaks in child care settings [for typhoid fever, see subsection 64D-3.040(6), F.A.C.]. In the event of an outbreak in a child care setting of one of these diseases, the county health department director or administrator or their designee shall implement control procedures as defined in “Guidelines for Control of Outbreaks of Enteric Disease in Child Care Settings,” dated March 2000, incorporated by reference, available online at: www.doh.state.fl.us/ disease%5Fctrl/epi/surv/enteric.pdf.

Editorial Note: Formerly 64D-3.013.

 

64D-3.041 Epidemiological Investigations.

Editorial Note: Formerly 64D-3.018.

 

64D-3.042 STD Testing Related to Pregnancy

(4) Emergency Departments of hospitals licensed under chapter 395, F.S. may satisfy the testing requirements under this rule by referring any woman identified as not receiving prenatal care after the 12th week of gestation, to the county health department.

(a) The referral shall be in writing; and

(b) A copy shall be submitted to the county health department having jurisdiction over the area in which the emergency department is located.

Editorial Note: Formerly 64D3.019.

 

64D-3.043 Tuberculosis Treatment and Follow-up.

(1) An individualized treatment plan shall be prescribed by providers licensed under Chapters 458, 459, or 464 F.S., for each person in their care who has suspected or confirmed active Tuberculosis.

(b) The treatment plan must be documented on TB Medical Report and Treatment Plan, DH Form 1173, 02/98, incorporated by reference, available online at: www.doh.state. fl.us/disease%5Fctrl/tb/tbforms/dohpdfforms/1173/DH1173-T BTxPlan02-98.pdf.

(2) The county health department director, administrator or their designee shall document the case management approach as defined in Department guidelines “Tuberculosis (TB) Case Management/Team Approach,” 4/98, incorporated by reference, available from the Department of Health, Bureau of TB and Refugee Health, 4052 Bald Cypress Way, Bin A-09, Tallahassee, Florida 32399-1720.

Editorial Note: Formerly 64D-3.024.

 

64D-3.044 Allocation Methodology for the Distribution of Funds Appropriated for Tuberculosis Control.

Editorial Note: Formerly 64D-3.025.

 

64D-3.045 Execution of Certificate for Involuntary Hold for Tuberculosis.

(2) The treating physician shall complete the form, “Certificate of Physician Pursuant to Section 392.565, F.S., Requesting an Order for Involuntary Hold and Petition for Emergency Hearing,” DH Form 1201, 01/98, incorporated by reference, available at the local county health department or by contacting the A.G. Holley State Hospital, 1199 Lantana Road, Lantana, Florida 33462-1514, [phone]. The certificate shall state that the person appears to meet the requirements specified in Section 392.565, F.S., as well as the following criteria:

(3) The treating physician shall send the completed “Certificate of Physician Pursuant to Section 392.565, F.S., Requesting an Order for Involuntary Hold and Petition for Emergency Hearing”, incorporated by reference in subsection 64D-3.045(2), F.A.C., by facsimile to the Medical Executive Director of A.G. Holley State Hospital.

(4) If the Medical Executive Director agrees that the person meets the criteria for involuntary hold, the designee of the State Health Officer shall sign an “Order for Involuntary Hold,” DH Form 1202, 01/98, incorporated by reference, available at A.G. Holley State Hospital, 1199 Lantana Road, Lantana, Florida 33462-1514, [phone].

Editorial Note: Formerly 64D-3.026.

 

64D-3.046 Immunization Requirements: Public and Nonpublic Schools, Grades Preschool, and Kindergarten through 12, and Adult Education Classes.

(1) Immunization and Documentation Requirements –

1. DH Form 680, Florida Certification of Immunization (July 2001), incorporated by reference, available from DOH county health departments (DOH CHDs) or physicians’ offices.

3. For exemption from the rubeola immunization the practitioner must include with DH Form 680, Florida Certification of Immunization, incorporated by reference in subsection 64D-3.046(1), F.A.C., documentation on their own stationery of the physician’s request for exemption, asserting that the student had an illness comprised of a generalized rash lasting three or more days, a fever of 101 degrees Fahrenheit or greater, a cough, and/or coryza, and/or conjunctivitis and, in the physician’s opinion, has had the ten-day measles (rubeola) or serologic evidence of immunity to measles.

(c) Forms are to be fully executed by a practitioner licensed under Chapters 458, 459, 460, F.S., or their authorized representative (where permitted in the particular certification) per instructions for the appropriate school year as provided in DH Form 150-615, Immunization Guidelines- Florida Schools, Child Care Facilities and Family Day Care Homes (July 2002), incorporated by reference, available online at: www.doh.state.fl.us/disease_ctrl/immune/schoolguide.pdf.

(d) DH Form 681, Religious Exemptions for Immunizations (English/ Spanish/ Haitian-Creole) (February 2002), incorporated by reference, available at DOH CHDs, must be issued and signed by the local county health department medical director or designee.

(e) Otherwise required immunizations not performed must be accounted for under the Temporary or Permanent Medical Exemptions, DH Form 680, Florida Certification of Immunization, Parts B and C, incorporated by reference in subsection 64D-3.046(1), F.A.C.

(3) Documentation Requirements for Schools:

(c) Compliance Reporting

1. Each public and nonpublic school with a kindergarten and/or seventh grade shall submit an annual compliance report. The report shall be completed on DH Form 684, Immunization Annual Report of Compliance for Kindergarten and Seventh Grade (November 1996), incorporated by reference, available at DOH CHDs. The report shall include the immunization status of all children who were attending kindergarten and seventh grades at the beginning of the school year. The report shall be forwarded to the county health director/administrator no later than October 1 of each school year where the data will be compiled on DH Form 685, Kindergarten and Seventh Grade Annual Report of Compliance County Summary (November 2006), incorporated by reference, available at DOH CHDs; or electronically generated by the Department of Education.

(6) Florida SHOTS (State Health Online Tracking System) Opt Out Provision – Parents or guardians may elect to decline participation in the Florida immunization registry, Florida SHOTS, by submitting a completed Florida SHOTS Notification and Opt Out Form to the Department of Health. The form, either a DH Form 1478 (English) or DH Form 1478S (Spanish) or DH Form 1478H (Haitian-Creole), incorporated by reference, is available from the DOH Bureau of Immunization, 4052 Bald Cypress Way, Bin # A-11, Tallahassee, FL 32399-1719. The immunization records of children whose parents choose to opt-out will not be shared with other entities that are allowed by law to have access to the child’s immunization record via authorized access to Florida SHOTS.

(7) Florida SHOTS Private Provider Participation – Any health care practitioner licensed in Florida under Chapters 458, 459 or 464, F.S., may request authorization to access Florida SHOTS by filling out a DH Form 1479, Authorized Private Provider User Agreement for Access to Florida SHOTS (Florida State Health Online Tracking System) (November 2000), incorporated by reference, available from the DOH Bureau of Immunization, 4052 Bald Cypress Way, Bin # A-11, Tallahassee, FL 32399-1719. The DH Form 1479 will be returned to the Department of Health for processing and authorization to access Florida SHOTS. Notification of access approval and instructions for accessing Florida SHOTS will be provided by the Department of Health. The authorized user and the applicable licensing authority or agency shall notify the Department of Health, Bureau of Immunization Florida SHOTS personnel when an authorized user’s license or registration has expired or has been suspended or revoked.

(8) Florida SHOTS School and Licensed or Registered Child Care Facility Participation – Any public or nonpublic school, or licensed or registered child care facility may request authorization to access Florida SHOTS by completing a DH Form 2115, Authorized School and Licensed or Registered Child Care Facility User Agreement for Access to Florida SHOTS (November 2000), incorporated by reference, available from the DOH Bureau of Immunization, 4052 Bald Cypress Way, Bin # A-11, Tallahassee, FL 32399-1719. The DH Form 2115 will be returned to the Department of Health for processing and authorization to access Florida SHOTS. Notification of access approval and instructions for accessing Florida SHOTS will be provided by the Department of Health. The authorized user and the applicable licensing authority or agency shall notify the Department of Health, Bureau of Immunization Florida SHOTS personnel when an authorized user’s license or registration has expired or has been suspended or revoked.

Editorial Note: Formerly 64D-3.011.

 

64D-3.047 Enforcement and Penalties.

Editorial Note: Formerly 64D-3.020.

 

64D-3.048 List of Documents Incorporated by Reference – Deleted